Drug Database
Back to search

Netherlands· NL-ff86a175d358

Litak, oplossing voor injectie 2 mg/ml

A cladribine product containing cladribine, registered in Netherlands by Lipomed GmbH. The same ATC class is registered in 14 of our 19 countries.

ATC L01BB04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLitak, oplossing voor injectie 2 mg/mlATCL01BB04REGISTER NO.NL-ff86a175d358PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cladribineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cladribine is registered in 14 of 19 countries.

Countries holding a registration under ATC L01BB04 (cladribine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search cladribine products by name

Cladribine · ATC L01BB04

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
CLADRIBINE
Manufacturer
Lipomed GmbH
Country
Netherlands (NL)
ATC code
L01BB04
ATC class
Cladribine
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/04/275

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

409 interactions on record for cladribine.

Graded by severity as the source publishes them — 326 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cladribine against other medicinesHow interaction checks work

Cladribine · interactions on record

409 records

  • 326 severe
  • 79 moderate
  • 4 info

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cladribine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cladribine products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Leuject
  • Belgium · Leustatin
  • Bulgaria · Леуджект
  • Czechia · Leuject
  • Germany · Leustatin
  • Spain · Leustatin
  • Finland · Leuject
  • France · Leustatine
  • United Kingdom (Northern Ireland) · Cladribine Zentiva, Leustat
  • Greece · Leustatin
  • Croatia · Leuject
  • Hungary · Leuject
  • Iceland · Mavenclad
  • Italy · Leustatin
  • Liechtenstein · Mavenclad
  • Luxembourg · Leustatin
  • Norway · Leuject, Mavenclad
  • Poland · Biodribin, Leuject
  • Portugal · Cladribina Generis, Leustatin
  • Romania · Leuject
  • Sweden · Leuject
  • Slovenia · Leuject

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f24cb8c4-de31-4736-90f8-3e2bd0aa692c
GET /v1/drugs/f24cb8c4-de31-4736-90f8-3e2bd0aa692c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/litak-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Cladribine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp71772",
  "excipients": [
    "NATRIUMCHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "CLADRIBINE"
  ],
  "leaflet_url": null,
  "authorised_at": "2004/04/14",
  "procedure_number": "EMEA/H/C/000504",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/04/275",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about cladribine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console